Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11137485 | 0.76 | GRM5 (0.40) | GRM5FFAR1APPKDM4ETP53 | |
| SCHEMBL18897534 | 0.76 | APP (0.59) | APPTP53ACHE | |
| SCHEMBL29114228 | 0.76 | GRM5 (0.43) | GRM5FFAR1TGM2CA1CA2 | |
| SCHEMBL7035142 | 0.76 | APP (0.48) | APPKDM4ECA1CA2CA9 | |
| SCHEMBL21261234 | 0.76 | CYP2A6 (0.38) | TGM2KDM4E | |
| SCHEMBL7717366 | 0.76 | GRM5 (0.50) | GRM5FFAR1APPKDM4ETP53 | |
| SCHEMBL10300106 | 0.76 | GRM5 (0.50) | GRM5FFAR1APPKDM4ETP53 | |
| SCHEMBL718949 | 0.76 | GRM5 (0.50) | GRM5FFAR1APPKDM4ETP53 | |
| SCHEMBL29114205 | 0.76 | KIF11 (0.44) | TGM2 | |
| SCHEMBL840229 | 0.75 | APP (0.55) | GRM5FFAR1APPKDM4ECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106588721-A | Vinyl thioether compound and preparation method thereof | 同济大学 | 2017-04-26 | — | — | CN | disclosed |
| US-20170007589-A1 | Compositions For Treating Retinal Degeneration And Methods of Production and Use Thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007589-A1 | Compositions For Treating Retinal Degeneration And Methods of Production and Use Thereof | ALDH1A2, PDE6D, PDE6H | GRM5 1374/4885FFAR1 1673/4885APP 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.